Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TNFSF11

TNFSF11

Brief Information

Name:Tumor necrosis factor ligand superfamily member 11
Target Synonym:Osteoclast differentiation factor,TRANCE,TNFSF11,TNF-related activation-induced cytokine,Tumor necrosis factor ligand superfamily member 11,CD254,TNF Superfamily Member 11,Osteoprotegerin Ligand,Receptor Activator Of Nuclear Factor Kappa B Ligand,Tumor Necrosis Factor Superfamily Member 11,ODF,RANKL,OPGL,CD254 Antigen,HRANKL2,TNLG6B,OPTB2,SOdf,RANK Ligand,Tumor Necrosis Factor (Ligand) Superfamily, Member 11,Receptor Activator Of Nuclear Factor Kappa-B Ligand,Tumor Necrosis Factor Ligand 6B
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

RAL-H5265-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.574 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

RAL-H5240-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-TNFSF11 (human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TNFSF11, His Tag (active trimer) (Cat. No. RAL-H5240) with an affinity constant of 0.274 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

RANKL,CD254,TRANCE,OPGL,ODF

Background

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Denosumab biosimilar(Reliance Life Sciences) R-TPR-045 Approved Reliance Life Sciences DenosuRel India Osteoporosis, Postmenopausal; Bone metastases Reliance Life Sciences 2022-02-01 Bone metastases; Osteoporosis, Postmenopausal Details
Denosumab NSC-744010; AMG-162; ENZ-215 Approved Amgen Inc Prolia, Xgeva, Pralia, Ranmark Mainland China Osteoporosis, Postmenopausal Amgen Inc 2010-05-26 Fractures, Bone; Prostatic Neoplasms, Castration-Resistant; Feeding and Eating Disorders; Giant Cell Tumors; Prostatic Neoplasms; Arthropathy, Neurogenic; Breast Neoplasms; Osteogenesis Imperfecta; Giant Cell Tumor of Bone; Colorectal Neoplasms; Bone Neoplasms; Lung Neoplasms; Fractures, Spontaneous; Lymphoma; Granuloma, Giant Cell; Hypersensitivity, Delayed; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Osteoblastoma; Anorexia Nervosa; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Fibroma; Neoplasms; Hematologic Neoplasms; Endocrine Gland Neoplasms; Kidney Neoplasms; Cataract; Solid tumours; Head and Neck Neoplasms; Hematopoietic stem cell transplantation (HSCT); Osteoporosis; Parathyroid Neoplasms; Carcinoma; Bone Diseases, Metabolic; Bone metastases; Osteoporosis, Postmenopausal; Chondroblastoma; Colonic Neoplasms; Hypercalcemia; Kidney Diseases; Arthritis, Rheumatoid; Smoldering Multiple Myeloma; Hodgkin Disease; Bone Cysts, Aneurysmal; Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) Phase 3 Clinical Qilu Pharmaceutical Co Ltd Osteoporosis, Postmenopausal; Neoplasms Details
Recombinant human anti-RANKL antibody (Innovent Biologics) IBI-307 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Osteoporosis Details
Denosumab biosimilar (Intas Biopharmaceuticals) Phase 3 Clinical Intas Biopharmaceuticals Osteoporosis, Postmenopausal Details
Denosumab biosimilar (Alphamab) KN-012 Phase 3 Clinical Suzhou Alphamab Co Ltd Osteoporosis, Postmenopausal Details
LZM-004 LZM-004 Phase 1 Clinical Livzon(Group) Pharmaceutical Factory Bone metastases Details
Recombinant human anti-RANKL antibody (Hisun Pharma) HS629 Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Solid tumours; Bone metastases Details
Recombinant human anti-RANKL momoclonal antibody (Hualan Biological Engineering) Phase 1 Clinical Hualan Genetic Engineering Co Ltd Solid tumours; Osteoporosis, Postmenopausal Details
Denosumab biosimilar (Sandoz) GP-2411 Novartis Pharma Ag, Sandoz Details
Denosumab biosimiliar (Celltrion) CT-P41 Phase 1 Clinical Celltrion Details
Denosumab biosimilar (Samsung Bioepis) SB-16 Samsung Bioepis Details
Denosumab biosimilar(Fresenius Kabi) FKS-518 Fresenius Kabi Swissbiosim Gmbh Details
Denosumab biosimilar (Boan Biopharma/Luye) LY-06006; LY-01011; BA-1102; BA-6101 Phase 3 Clinical Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd Bone metastases; Osteoporosis; Neoplasms; Osteoporosis, Postmenopausal; Bone Neoplasms; Neoplasm Metastasis Details
GB-223 GB-223 Phase 1 Clinical Genor Biopharma Co Ltd Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Giant Cell Tumor of Bone Details
CEP-37251 ART-010; EGX-010; CEP-37251 Teva Details
Denosumab biosimilar (Henlius ) HLX-14; HLX14 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Osteoporosis, Postmenopausal Details
Denosumab biosimilar (AryoGen) Phase 3 Clinical Aryogen Biopharma Osteoporosis Details
KP-46 KP-46; FFC-11; LX-001; AP-002 Phase 2 Clinical University Of Heidelberg, Meram Solid tumours Details
Denosumab biosimilar(Shanghai Hansoh) HS-20090; HS-20090-2 Phase 1 Clinical Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd Bone metastases; Solid tumours; Neoplasms; Osteoporosis, Postmenopausal; Bone Diseases; Hypercalcemia; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases Details
Denosumab biosimilar(Alvotech Swiss) AVT-03 Phase 3 Clinical Alvotech Swiss Ag Osteoporosis, Postmenopausal Details
Denosumab biosimilar(Mabxience) Phase 3 Clinical Mabxience Sa Osteoporosis, Postmenopausal Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message